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Letter to Editor Rheumatology
Reply to: 
About the AIRTRIP 
randomised clinical trial     
Sirs,
We thank Drs Dincses and Seyahi for 
their interest in our work (1, 2), which 
gives us the opportunity to further expand 
some points.
The current status of the medical litera-
ture is that a case series, even if prospec-
tive, is inevitably labelled with a low C 
level of evidence, based on case series 
and expert opinion. In this setting, it be-
comes difficult even to obtain the active 
drug to administer to the patients, since 
both hospitals and drug companies are 
reluctant to give it. On the other hand, 
a randomised controlled trial (RCT) is 
graded as an A class of evidence, and 
considered as the gold standard. This is 
also justified by the fact that a RCT by 
definition necessitates a rigid protocol. 
For instance, our protocol mandated a 
quick tapering of all the drugs, except 
colchicine, within 6 weeks. We agree that 
anakinra has a spectacular effect when 
used in the correctly selected patients, 
but only a RCT has the strength to dem-
onstrate this in the modern era. This issue 
is completely unrelated to drug licensing. 
This study was investigator-initiated. 
SOBI provided anakinra and placebo as 
part of an unrestricted institutional grant, 
and had no role in the design and conduct 
of the study and in the preparation of the 
manuscript. SOBI is currently evaluating 
the outcomes of this study and potential 
next steps.
We used a withdrawal design consisting 
of 2 parts: an open-label treatment period 
in which anakinra was administered daily 
for 60 days, followed by a double-blind 
withdrawal period, in which patients who 
had a sustained complete response in part 
1 were randomised to receive anakinra or 
placebo daily for up to 6 months. This de-
sign was aimed to minimise the exposure 
to placebo (3); this method was similarly 
used to demonstrate the efficacy of anak-
inra in the cryopyrin-associated periodic 
syndromes (4). Theoretically, it would 
select responding patients, but in prac-
tice we had the situation in which ALL 
the patients had a complete sustained 
response to the active drugs, and all of 
them entered the second double-blind 
withdrawal phase. The possible enrich-
ment of a population with responders in 
the second phase is a theoretical concern, 
but not applicable to this specific study.
Even if the original proposal to treat pa-
tients with colchine-resistant and steroid-
dependent recurrent pericarditis with 
anti-IL1 treatment come from the paedi-
atric experience of treating children with 
autoinflammatory disorders, it was clear 
to us that the vast majority of patients in 
real life are adults. For this reason only 
one patient included in our study was in 
the paediatric age range (15 years old) 
and the remaining 20 patients were adults 
(aged >18 years). The paediatric patient 
was enrolled at the Gaslini Paediatric In-
situte, while the other 20 adults patients 
were enrolled in Torino and Bergamo re-
ferral centres mainly devoted to the care 
of adults with pericarditis (Torino is a 
cardiological centre, and Bergamo is an 
internal medicine centre).
In our study colchicine resistance indicat-
ed that all the patients continued to suffer 
recurrences despite colchicine therapy, 
and we think that this is clearly brought 
up in our paper.
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